Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6VP | ISIN: US04335A1051 | Ticker-Symbol:
NASDAQ
15.05.25 | 21:59
6,250 US-Dollar
+2,88 % +0,175
1-Jahres-Chart
ARVINAS INC Chart 1 Jahr
5-Tage-Chart
ARVINAS INC 5-Tage-Chart

Aktuelle News zur ARVINAS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.05.Where Arvinas Stands With Analysts3
05.05.Citi cuts Arvinas stock price target to $9.50, keeps neutral rating2
05.05.Arvinas stock rating cut, price target slashed to $11 at Truist2
02.05.Arvinas stock rating cut to hold at TD Cowen after trial cancellations2
ARVINAS Aktie jetzt für 0€ handeln
02.05.Arvinas targets regulatory filing for Vepdegestrant in metastatic breast cancer by 20251
01.05.Arvinas stock rating cut, price target slashed at Jefferies5
01.05.ARVINAS, INC. - 10-Q, Quarterly Report2
01.05.Goldman Sachs cuts Arvinas stock target to $8, maintains neutral4
01.05.Arvinas, Entrada cut staff; Merck builds US hub for Keytruda7
01.05.Arvinas stock slides after eliminating trials, reducing workforce4
01.05.Pre-market Movers: Zoomcar, NanoVibronix, Arvinas, E2open Parent, TTM Technologies677NEW DELHI (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.55 A.M. ET).In the Green Zoomcar Holdings, Inc. (ZCAR) is up over 123%...
► Artikel lesen
01.05.Arvinas-Aktie stürzt nach Personalabbau und Studienkürzungen ab6
01.05.Arvinas stock tumbles following workforce reduction and trial removals4
01.05.Arvinas Inc.: Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update108- Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings - - Presented first-in-human data for the Company's first neuroscience program with ARV-102...
► Artikel lesen
30.04.A Peek at Arvinas' Future Earnings1
30.04.Arvinas Q1 2025 Earnings Preview4
28.04.ARVINAS, INC. - 8-K, Current Report2
28.04.Arvinas Inc.: Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting185- ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule...
► Artikel lesen
23.04.Arvinas Inc.: Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting209- Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial - NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN)...
► Artikel lesen
21.04.Arvinas Inc.: Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research (AACR) Annual Meeting1
Seite:  Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1